Last reviewed 2026-04-23 · How we verify

Bendamustine-EAM

Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine).

Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine). Used for Conditioning regimen prior to autologous hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies.

At a glance

Mechanism of action

Bendamustine functions as a bifunctional alkylating agent that binds to DNA and causes interstrand cross-links, leading to cell death. The EAM regimen combines bendamustine with etoposide (a topoisomerase II inhibitor) and cytarabine (a nucleoside analog), creating a multi-modal chemotherapy approach. This combination is typically used as a conditioning regimen prior to autologous stem cell transplantation in hematologic malignancies.

Approved indications

• Conditioning regimen prior to autologous hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies

Common side effects

• Myelosuppression
• Nausea and vomiting
• Mucositis
• Infection
• Diarrhea

Key clinical trials

• Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bendamustine-EAM CI brief — competitive landscape report
• Bendamustine-EAM updates RSS · CI watch RSS
• Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI